Ovid Therapeutics to Participate in Two Upcoming Investor Conferences

NEW YORK, Nov. 29, 2016 (GLOBE NEWSWIRE)—Ovid Therapeutics, a privately-held biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced its participation in two upcoming investor conferences:

  • Citi 2016 Global Healthcare Conference

Members of the Company’s management team will participate in one-on-one meetings with investors on Wednesday, December 7, 2016, at the Lotte Palace Hotel in New York, NY.

  • BMO Capital Markets 2016 Prescription for Success Healthcare Conference

Yaron Werber, M.D., chief business and financial officer of Ovid, will present on Wednesday, December 14, 2016, at 4:40 p.m. ET at the InterContinental Barclay Hotel in New York, NY.

About Ovid Therapeutics Inc.

Ovid Therapeutics Inc. is a privately held, New York-based, biopharmaceutical company committed to transforming the lives of patients with orphan diseases of the brain. Ovid focuses on patients and their unmet medical needs. Using the significant operational, product development, and business development experience of its management team, Ovid aims to become a leading neurology company, with multiple products and a rich pipeline, coupled with compelling research and development. Ovid has raised $80M in financings led by Fidelity Management and Research Company and including Cowen Private Investments, Sanofi-Genzyme BioVentures, Tekla Capital Management, Sphera Global Healthcare Fund, Jennison Associates, Redmile Group, DoubleLine Equity Healthcare Fund, and Cormorant Asset Management, as well as additional blue chip mutual funds and leading life sciences investors.

Contacts

Investors:
Burns McClellan
Steve Klass, 212-213-0006
Sklass@burnsmc.com
Media:
Pure Communications, Inc.
Katie Engleman, 910-509-3977
katie@purecommunicationsinc.com